Protagonist Therapeutics Announces Executive and Director Compensation Changes
Ticker: PTGX · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1377121
Sentiment: neutral
Topics: governance, compensation, executive-changes
TL;DR
Protagonist Therapeutics updated exec pay and board structure effective Jan 1, 2025.
AI Summary
Protagonist Therapeutics, Inc. announced on January 1, 2025, changes in its executive and director compensation arrangements. The filing details the election of new directors and the appointment of certain officers, alongside updates to compensatory arrangements for key personnel. This 8-K filing provides transparency regarding the company's governance and executive compensation structure.
Why It Matters
Changes in executive and director compensation can signal shifts in company strategy or performance, impacting investor confidence and employee morale.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance and compensation updates, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- January 1, 2025 (date) — Effective date of reported changes
- Delaware (jurisdiction) — State of incorporation
- 001-37852 (company_id) — Commission File Number
FAQ
What specific changes were made to the compensatory arrangements for certain officers?
The filing indicates updates to compensatory arrangements for certain officers, but the specific details of these changes are not provided in this summary section of the 8-K.
Who are the newly elected directors?
The filing mentions the election of new directors, but their names are not listed in the provided text.
What is the effective date of the reported changes?
The earliest event reported is dated January 1, 2025.
What is the Commission File Number for Protagonist Therapeutics, Inc.?
The Commission File Number for Protagonist Therapeutics, Inc. is 001-37852.
What is the primary business of Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 391 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2025-01-06 16:05:23
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
Filing Documents
- tm251959d1_8k.htm (8-K) — 24KB
- 0001104659-25-001304.txt ( ) — 192KB
- ptgx-20250101.xsd (EX-101.SCH) — 3KB
- ptgx-20250101_lab.xml (EX-101.LAB) — 33KB
- ptgx-20250101_pre.xml (EX-101.PRE) — 22KB
- tm251959d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective January 1, 2025, Suneel Gupta, Ph.D., Protagonist Therapeutics, Inc.'s Chief Development Officer, transitioned to Executive Vice President, Clinical Development. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: January 6, 2025 By: /s/ Asif Ali Asif Ali Chief Financial Officer